立方制药：贝派度酸片药品注册临床试验申请获受理

Core Viewpoint - Lifan Pharmaceutical has received a clinical trial application acceptance notice from the National Medical Products Administration for its drug Beipaidu Acid Tablets (180mg), aimed at reducing the risk of myocardial infarction and coronary artery revascularization in patients unable to accept recommended statin therapy [1] Group 1 - The proposed indication for the clinical trial is for adult patients with cardiovascular disease or those at high risk of cardiovascular events who cannot use statin therapy [1]